For instance, in glioblastoma (GBM), pharmacological inhibitors of PRMT5 have been shown to reduce the proliferation of GBM stem cells and enhance the sensitivity of proneural subpopulations by altering the splicing patterns of cell-cycle related gene products (27). This evidence concerns the gene PRMT5 and glioblastoma.